Entest BioMedical and Quantum Advisors sign Letter of Intent

Nov 3 2009

Entest BioMedical Inc. (OTCBB: ENTB) announced today that it has signed a Letter of Intent with Quantum Advisors, a San Diego based biotechnology consulting firm, to assist Entest with the development of its Stem Cell Therapeutic Treatment for Chronic Obstructive Pulmonary Disease (COPD).

An Entest spokesperson stated that Quantum’s anticipated role in this research will be to work with Company scientists, Contract Research Organizations (CROs) and Regulatory authorities in moving forward with clinical testing of Entest’s patent pending technology. Quantum will also be involved with assisting the Company with its Investigational New Drug (IND) submission to the FDA.

David Koos, Entest’s Chairman & CEO, said, “Our relationship with Quantum is extremely valuable to our Company. Not only is it planned for them to be working with us to develop our stem cell therapy for COPD, it is also planned that they will help identify appropriate Joint Venture candidates for commercialization of this technology. What this means to COPD patients -- we are going to do all that is possible to bring this treatment for COPD to doctors and hospitals at the earliest possible date.”